Drug Type Bispecific antibody |
Synonyms- |
Target |
Mechanism CD16a antagonists(Low affinity immunoglobulin gamma Fc region receptor III-A antagonists), HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Breast Cancer | Preclinical | US | 15 Mar 2024 |